30 closest matches · ranked by relevance
Third Degree Burn · Burns · Wound Infection
Primary: Percent Autograft Take on Wounds Prepared by StrataGraft™ Skin Tissue. — 97.7; 96.7 Percent Area of Autograft Take (%)
Ulcer · Skin Ulcer · Wounds and Injuries
Primary: Number of Wounds With Complete Healing — 9; 13; 16; 20 number of wounds — p=0.366
Deep Partial-thickness Burn
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 46 Participants
Skin Wound · Burns · Trauma-related Wound
Primary: Percentage of Participants Who Achieved Confirmed Complete Closure of StrataGraft Treatment Sites Without Autograft Within 12 Weeks of StrataGraft Application — 100…
Skin Wound · Burns · Trauma-related Wound
Primary: Number of Participants With Wound Closure of the Treatment Sites at Three Months — 29; 29 Participants
Epidermolysis Bullosa Dystrophica · Epidermolysis Bullosa
Primary: Number of Wounds by Healing Category Per Investigator Visual Assessment — 35; 5; 2; 28 wounds
Burn, Thermal
Primary: Percent Area of Treatment Sites Requiring Autografting by Month 3 — 4.33; 102.10 percentage of treatment sites — p=<0.0001
Burn Scar · Skin Graft Scar
Primary: Contracture of Scar Surface Area (Percentage of Original Area) — 97; 97 percentage
Epidermolysis Bullosa
Primary: Percentage of Grafts Successfully Treated — 78 Percentage of grafts
Ectropion · Skin Neoplasms
Primary: Graft Size Change — 10 percent change in graft
Full-thickness Skin Defects · Degloving Injuries · Crush Injuries
Primary: Incidence of Treatment Area Healing — 30; 34 Treatment Areas — p=.005
Burns · Trauma · Venous Ulcers
Primary: Rate of Wound Healing — 12.1; 21.3 Days
Sclerotic Graft Versus Host Disease · Imatinib Mesylate
Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline
Wound of Skin
Primary: Change of Pain on Harvesting of Skin at Donor Site. — 2.6 millimeters
Graft Versus Host Disease
Primary: CXCL10 in Skin — 273; 41; 7.5 Skin CXCL10 femtograms/micrograms — p=<0.01
Venous Leg Ulcer
Primary: Complete Healing of the Study Ulcer by Week 16. — 201; 176 participants — p=0.1030
Burns
Primary: Incidence of RECELL-treated Area Closure Compared to Control at 4 Weeks (Non-inferiority) — 82; 87; 82; 83 Participants
Burns
Primary: Number of Participants With Confirmed Treatment Area Closure of RECELL-treated Wounds Compared to Control (Non-inferiority) — 24; 22; 2; 4 Participants
Acute Graft Versus Host Disease
Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients
Donor Site Complication
Primary: Percentage of Participants Who Had > 95 % Epithelialization at Day 10 — 0 percentage of participants
Vitiligo
Primary: Percent Repigmentation of Target Lesion — 0.21; 0.17 percentage of repigmentation
Wounds
Primary: Intra-individual Difference in Time to Wound Closure — -0.8 days — p==0.0232
Graft Versus Host Disease · Systemic Scleroderma
Primary: Significant Clinical Response — 9; 10 participants
Burn Injury · Skin Graft
Primary: Part A: Number of Participants With Healing — 3; 21; 2; 22 Participants
Split-thickness Skin Graft Donor Sites
Primary: Pain — 4.2; 2.5; 1.1 units on a scale
Normal Female Volunteers
Primary: Identification of the Full Set of Y-chromosome Short Tandem Repeats in Each Bioopsy. — 3; 1; 0; 0 Participants
Wounds
Primary: Intra-individual Difference in Time to Wound Closure — -1.4 days — p=<0.0001
Chronic Granulomatous Disease
Primary: Percentage of Participants With Engraftment — 100 percentage of participants
Donor Site Complication
Primary: Number of Participants With Treatment-related AEs and SAEs (Including Infections and Bleeding) — 0; 0; 0; 0 Participants
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120